



CIN No : L24239MH1987PLC043662

Date: 30th May 2017

To,

Listing Department,
Bombay Stock Exchange,
Dalal Street Fort,
Mumbai - 400001

Subject: Outcome of Board Meeting.

Dear Sir,

As per SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 we are herein providing the outcome of the Board Meeting held on 30th May 2017 commenced at 1:10 p.m. and concluded at 5.00 p.m. as under:

Chairperson:

Dr. D. N. Medhora occupied the Chair as the Chairperson of the Meeting


Minutes of previous Board Meeting:

Minutes of the previous meeting were approved.

Approval of Audited Financial Results and Auditor's Report:

The Audited Financial Results along with Auditor's Report as issued by Savla & Associates, Chartered Accounts for the year ended 31st March 2017 were approved and taken on records by the Board.

A Copy of the said results will be published in the Newspaper as per SEBI (LODR) Regulations.





CIN No: L24239MH1987PLC043662

Dividend

Final Dividend at the rate of 6% to Equity shareholders was approved by the Board and decided to be proposed for Shareholders approval at the upcoming Annual General meeting.

Notice of AGM, Board's Report, Management Statement, etc.

The Board of Directors approved the various drafts of AGM Notice, Director's Report, Secretarial Audit Report, Corporate Governance Report, Management Statement, etc. as placed before them for the upcoming Annual General Meeting and Annual Report.

Reappointment of Directors

The Board approved reappointment of Mr. Fredun Medhora as Managing Director and Dr. Daulat Medhora as Whole Time Director to be placed before the Shareholders for their approval.

Overdraft facility from Keynote Ltd. for Rs. 1 Crore and 50 Lakhs

The Board consented to avail a overdraft facility to the extent of 1.5 crore rupees from Keynote Ltd. based on the agreement as tabled at the Meeting.

Thanking you

Yours Faithfully

For FREDUN PHARMACEUTICALS LIMITED*to medhora***DIRECTOR**